Prostate Adenocarcinoma
251
57
99
89
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
67 trials with published results (27%)
Research Maturity
89 completed trials (35% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
11.2%
28 terminated out of 251 trials
76.1%
-10.5% vs benchmark
7%
18 trials in Phase 3/4
75%
67 of 89 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 89 completed trials
Clinical Trials (251)
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
PSMA PET Imaging of Recurrent Prostate Cancer
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer